Authorized purpose: The V8 and V7 diagnostic ultrasound systems and probes obtain ultrasound images and analyze body fluids across the labeled fetal, abdominal, gynecologic, intraoperative, pediatric, small-organ, cephalic, transrectal, transvaginal, musculoskeletal, urologic, cardiac, thoracic, transesophageal, and peripheral-vessel applications.
Clinical role
Diagnostic ultrasound imaging, fluid analysis, measurement, display, and analysis using the exact labeled probes and modes.
Keep in mind: Use only the exact labeled probes, applications, modes, patient populations, and care settings; output requires qualified-professional review.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: The V8 and V7 diagnostic ultrasound systems and probes obtain ultrasound images and analyze body fluids across the labeled fetal, abdominal, gynecologic, intraoperative, pediatric, small-organ, cephalic, transrectal, transvaginal, musculoskeletal, urologic, cardiac, thoracic, transesophageal, and peripheral-vessel applications.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Fetal/obstetric, abdominal, gynecologic, intraoperative, pediatric, small-organ, cephalic, transrectal, transvaginal, musculoskeletal, urologic, cardiac, thoracic, transesophageal, and peripheral-vessel anatomy Input: Ultrasound acquisitions and fluid information from supported probes, applications, patient populations, and operating modes.
Who uses it?Intended users: Appropriately trained healthcare professionals qualified for direct use of diagnostic ultrasound equipment.
What does the software produce?Output: Ultrasound images, measurements, Doppler or other mode-specific information, and fluid-analysis results for professional interpretation.
What is its most important limitation?Key limitation: Use only the exact labeled probes, applications, modes, patient populations, and care settings; output requires qualified-professional review.
Clinical takeaway. Clinical role: The V8 and V7 diagnostic ultrasound systems and probes obtain ultrasound images and analyze body fluids across the labeled fetal, abdominal, gynecologic, intraoperative, pediatric, small-organ, cephalic, transrectal, transvaginal, musculoskeletal, urologic, cardiac, thoracic, transesophageal, and peripheral-vessel applications.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical testing (acoustic output, biocompatibility, software function, cleaning and disinfection, safety) and validation of AI-based features. For expanded NerveTrack nerve detection, average accuracy was 90.3% (95% CI 88.6 to 92.0) on test data of 2,146 images from 18 subjects, with ground truth established by anesthesiologists and sonographers. The proposed device did not require clinical studies to demonstrate substantial equivalence. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
The V8 and V7 diagnostic ultrasound systems and probes obtain ultrasound images and analyze body fluids across the labeled fetal, abdominal, gynecologic, intraoperative, pediatric, small-organ, cephalic, transrectal, transvaginal, musculoskeletal, urologic, cardiac, thoracic, transesophageal, and peripheral-vessel applications.
The exact FDA document reports non-clinical testing (acoustic output, biocompatibility, software function, cleaning and disinfection, safety) and validation of AI-based features. For expanded NerveTrack nerve detection, average accuracy was 90.3% (95% CI 88.6 to 92.0) on test data of 2,146 images from 18 subjects, with ground truth established by anesthesiologists and sonographers. The proposed device did not require clinical studies to demonstrate substantial equivalence. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The device has been evaluated for acoustic output, biocompatibility, software function, cleaning and disinfection effectiveness as well as thermal, electrical, electromagnetic and mechanical safety," … "These are the details on validation of the AI algorithm used for all the new and improved AI-based features that includes expansion of the use of NerveTrack feature". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports non-clinical testing (acoustic output, biocompatibility, software function, cleaning and disinfection, safety) and validation of AI-based features. For expanded NerveTrack nerve detection, average accuracy was 90.3% (95% CI 88.6 to 92.0) on test data of 2,146 images from 18 subjects, with ground truth established by anesthesiologists and sonographers. The proposed device did not require clinical studies to demonstrate substantial equivalence. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "The device has been evaluated for acoustic output, biocompatibility, software function, cleaning and disinfection effectiveness as well as thermal, electrical, electromagnetic and mechanical safety," … "These are the details on validation of the AI algorithm used for all the new and improved AI-based features that includes expansion of the use of NerveTrack feature". Read from the exact FDA decision document on 2026-11-14.
No exact-submission and version-linked sensitivity endpoint is promoted; candidate or product-family values were not substituted.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No exact-submission and version-linked specificity endpoint is promoted; candidate or product-family values were not substituted.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FDA submission-specific verification and validation evidence for K223387
DesignFDA 510(k) regulatory decision material and submission-specific verification or validation evidence for K223387; this is regulatory evidence, not an independent clinical effectiveness study.
PopulationThe labeled population, anatomy, images, and test materials described in the exact FDA decision material for K223387; a broader clinical population is not established here.
Scopeexact submission
Tested versionV8 Diagnostic Ultrasound System, V7 Diagnostic Ultrasound System (K223387)
IndependenceSponsor or vendor study
K223387
The exact FDA material is submission-specific and should not be generalized to other versions, enabled options, sites, protocols, or clinical outcomes.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Ultrasound acquisitions and fluid information from supported probes, applications, patient populations, and operating modes.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Exact FDA evidence does not establish the complete local interface, identity, routing, display, report, fallback, or interoperability behavior for this submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-04 ·
AI processing
Source context, not route validation: The exact FDA package describes the V8 / V7 as general purpose, mobile, software-controlled diagnostic ultrasound systems that include AI-based BiometryAssist, ViewAssist and HeartAssist features. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The V8 / V7 are a general purpose, mobile, software controlled, diagnostic ultrasound system." … "The proposed V8 / V7 have included the BiometryAssist and ViewAssist which are based on AI version from the previously cleared HERA W9/ HERA W10 (K220043).". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Ultrasound images, measurements, Doppler or other mode-specific information, and fluid-analysis results for professional interpretation.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Ultrasound images, measurements, Doppler or other mode-specific information, and fluid-analysis results for professional interpretation.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the V8 / V7 as general purpose, mobile, software-controlled diagnostic ultrasound systems that include AI-based BiometryAssist, ViewAssist and HeartAssist features. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The V8 / V7 are a general purpose, mobile, software controlled, diagnostic ultrasound system." … "The proposed V8 / V7 have included the BiometryAssist and ViewAssist which are based on AI version from the previously cleared HERA W9/ HERA W10 (K220043).". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Samsung Healthcare USA's security advisories page, published under Boston Imaging (a Samsung company), posts vulnerability impact analyses and patch process statements for Samsung computed tomography, ultrasound and digital radiography modalities (including Log4j, Urgent11, BlueKeep and WannaCry analyses).
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: owning-domain press releases on usa.samsunghealthcare.com state that Boston Imaging is Samsung Medison's U.S. medical imaging business (unified as Samsung HME America, March 2026) and that Samsung Medison is an affiliate of Samsung Electronics. Corporate program statement; exact-release scope is not established.
Samsung Healthcare USA's security advisories page (Boston Imaging, a Samsung company) publishes product impact analyses and a patch process for Samsung CT, ultrasound and digital radiography modalities, with published advisories for Log4j, Urgent11, BlueKeep and WannaCry.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names Samsung Healthcare USA / Boston Imaging generally and does not scope this process to any specific product release; exact-release scope is not established.
Current vendor material is product-family context for K223387 only; exact release, enabled options, deployment, security, interoperability, pricing, and local workflow require confirmation.
product family · checked 2026-09-04
Vendor material is not exact-release evidence unless that linkage is separately proven.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
31Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not applicable - checked 2026-09-04 - Not applicable
CMS coverage-index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission
Exact FDA evidence does not establish the complete local interface, identity, routing, display, report, fallback, or interoperability behavior for this submission.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: The V8/H8, V7/H7, and V6/H6 diagnostic ultrasound systems and transducers obtain ultrasound images and analyze body fluids across the labeled fetal, abdominal, gynecologic, intraoperative, pediatric, small-organ, cephalic, transrectal, transvaginal, musculoskeletal, urologic, cardiac, thoracic, transesophageal, and peripheral-vessel applications.
Authorized purpose: Alturion Series diagnostic ultrasound systems acquire and display ultrasound images and fluid-flow information for the labeled fetal, abdominal, cardiac, cephalic, obstetric, musculoskeletal, ophthalmic, urologic, vascular, small-organ, and lung examinations.
Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; ophthalmic; urologic organs; and lung
Authorized purpose: WatchMate Software v1.2.0 processes transesophageal echocardiography data to reconstruct the left atrial appendage and assist preprocedural planning and device sizing during left-atrial-appendage closure.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.